[Honokiol inhibits the invasion and angiogenesis of U937 leukemia cells].
OBJECTIVE
To investigate the inhibiting effect of Honokiol (HNK) on the invasion and angiogenesis in U937 leukemia cells and the molecular mechanism.


METHODS
After treated with different concentrations of HNK, the growth inhibition rate of U937 cells was determined by MTT assay, and for the adhesion and invasion abilities were assessed using cell matrix adhesion technique and Transwell(TM); assay, respectively. VEGF, VEGFR1 and MMP-9 mRNA expression levels were detected by real-time quantitative RT-PCR (qRT-PCR). VEGF protein levels were determined by ELISA.


RESULTS
HNK could significantly inhibit the proliferation of U937 cells in a time- and dose-dependent manner. The adhesion and invasion abilities of U937 cells were suppressed after treated with a low concentration of HNK. The expressions of VEGF, VEGFR1 and MMP-9 were down-regulated by HNK in a dose-dependent manner.


CONCLUSIONS
HNK can inhibit the invasion and angiogenesis of U937 cells via down-regulating VEGF, VEGFR1 and MMP-9 expressions.
Department of Hematology, Baoding First Hospital, Baoding 071000, China.
Zhiyong
Z
Cheng
Department of Hematology, Second Affiliated Hospital, Hebei Medical University, Shijiazhuang 050000, China.
Fang
F
Xue
Department of Hematology, Hebei People's Hospital, Shijiazhuang 050000, China.
Suyun
S
Wang
Department of Hematology, Baoding First Hospital, Baoding 071000, China.
Fengyun
F
Wang
Department of Hematology, Baoding First Hospital, Baoding 071000, China.
Liqing
L
Liang
Department of Hematology, Baoding First Hospital, Baoding 071000, China.
Ping
P
Bai
Department of Hematology, Baoding First Hospital, Baoding 071000, China.
Yongsheng
Y
Bian
Department of Hematology, Baoding First Hospital, Baoding 071000, China.
Jianshe
J
Wan
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007938:Leukemia / Q000235:genetics / Q000473:pathology*; D017705:Lignans / Q000494:pharmacology* / Q000627:therapeutic use; D020780:Matrix Metalloproteinase 9 / Q000235:genetics; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000517:prevention & control; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics; D000498:Allyl Compounds; D010636:Phenols
D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; D017705:Lignans; D020780:Matrix Metalloproteinase 9; D042461:Vascular Endothelial Growth Factor A; D040281:Vascular Endothelial Growth Factor Receptor-1; C005499:honokiol; D000498:Allyl Compounds; D010636:Phenols